Abstract

In the past fifteen years there have been numerous reports on the treatment of scleroderma and related conditions with potassium para-aminobenzoate (Potaba - Glenwood Laboratories). The use of this ‘antifibrotic’ treatment is empirical. p-Aminobenzoic acid (PABA) is not known to affect fibrosis or fibrous tissue experimentally. Many bacteria require it for the synthesis of folic acid, and sulphonamides antagonise their utilisation of it.